SAN DIEGO, Oct. 22, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a Special Meeting of Stockholders (the "Special Meeting") on Friday 31 October 2014 at 10:30 a.m. AEDT (which is 4:30 p.m. US PDT on Thursday, October 30, 2014). The meeting will be held at the AGL Theatre in the Museum of Sydney located at the corner of Phillip and Bridge Streets in Sydney, Australia.
The Special Meeting will be audiocast and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in the Australia may access the call by dialing (02) 8223 9773. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly.
If you reside outside of Australia, the United States, or Canada, or if you prefer to access the audiocast through our website, please visit "Events & Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A replay of the audiocast will be available on our website after the call.
REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called "scaffolds" because of their temporary nature. The Company's scaffolds are being developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company has conducted clinical studies of its scaffold technologies; a total of 112 patients were enrolled in its most recent clinical trial in Australia, Brazil, Europe, and New Zealand, with enrollment completed during January 2014. The patients in this trial will be followed for a total of five years, with primary data to be obtained at nine and 12 months. The Company is now developing and testing its FantomTM scaffold, with initial human implants planned for late 2014 at multiple centers in Brazil and Europe. The Fantom scaffold has been designed to offer distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, no procedural time limitations, and standard storage and handling. REVA will require successful clinical results and regulatory approval before it can commercialize Fantom or any of its other products.
CONTACT: United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Investor Relations +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800
Source:REVA Medical, Inc.